^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Gastric Cancer
    Drug:Tyvyt (sintilimab) (PD1 inhibitor) +
    Fruzaqla (fruquintinib) (VEGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Fruquintinib Combined With Sintilimab as Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma

    Excerpt:
    ......
    Trial ID:
    NCT05625737
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    1519P - Fruquintinib plus sintilimab in patients (pts) with either treatment-naïve or previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results from a multicenter, single-arm phase II study

    Published date:
    10/16/2023
    Excerpt:
    Advanced gastric or GEJ adenocarcinoma pts with PD-L1 status of CPS ≥1, who had no prior systemic therapy or had failed at least first-line treatment were enrolled….F plus S provided favourable efficacy and manageable toxicity profile in pts with advanced gastric or GEJ adenocarcinoma...
    Trial ID:
    NCT03903705